Using next-generation sequencing data from patients with la/mUC receiving EV treatment to investigate the relationship between the genetic characteristics of tumor tissue and clinical outcomes, patients with abundant mutations in TP53, KDM6A, and MDM2 showed a better response to EV treatment [24]. The gene discussed is TP53; the disease is neoplasm.